ArticleNature2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
180citing papers in PubMed, 2 pooled it
28.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 2 syntheses or guidelines pooled it, 289 citations in OpenAlex.
- Immune escape of SARS-CoV-2 variants to therapeutic monoclonal antibodies: a system review and meta-analysis.Virology journal · 2023Pooled it
- Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review.Journal of cellular and molecular medicine · 2023Pooled it
- Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Implementation of an Online Drug-Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19.Open forum infectious diseases · 2025Trial
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.JAMA network open · 2024Trial
- A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations.Clinical drug investigation · 2023Trial
- Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.Antimicrobial agents and chemotherapy · 2022Trial
- Article
- SARS-CoV-2 Omicron BA.2.86 and JN.1 expand tropism in human proximal intestinal epithelium.Nature communications · 2026Article
- SARS-CoV-2 Omicron EG.5 and JN.1 induce enhanced pathogenicity in K18-hACE2 mice compared with the early Omicron subvariants.Lab animal · 2026Article
- Therapeutic Mechanisms of Traditional Kampo Medicines in the Management of Mild COVID-19 through Gut Microbiota Modulation.Internal medicine (Tokyo, Japan) · 2026Review
- A bireporter recombinant SARS-CoV-2 Omicron BA.5 forbioRxiv : the preprint server for biology · 2026Article
- A SARS-CoV-2 MNature communications · 2025Article
- Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice.iScience · 2025Article
- Article
- SARS-CoV-2 causes chronic lung inflammation and impaired respiratory capacity in aged Roborovski dwarf hamsters.Journal of virology · 2025Article
- Impact of Vaccination and Prior Infection on SARS-CoV-2 Viral Load in Preschool Children During the Omicron Pandemic.Vaccines · 2025Article
- From Delta to Omicron-Genetic Epidemiology of SARS-CoV-2 (hCoV-19) in Southern Poland.Pathogens (Basel, Switzerland) · 2025Article
- Article
120 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
53 authors at 9 institutions in 2 countries.
Ryuta Uraki *Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0890-1922
Maki Kiso *Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Shun Iida *Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2258-9031
Masaki Imai *Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6988-1975
Emi Takashita *Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9064-4699
Makoto Kuroda *Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Samantha LoeberDepartment of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Tadashi MaemuraInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Seiya YamayoshiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7768-5157
Seiichiro FujisakiCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.
Zhongde WangDepartment of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.ORCID http://orcid.org/0000-0003-2441-4729
Mutsumi ItoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Michiko UjieDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8266-020X
Yuri FurusawaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Ryan WrightInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Zhenlu ChongDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Seiya OzonoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1764-2937
Atsuhiro YasuharaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Hiroshi UekiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6557-0771
Yuko Sakai-TagawaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Rong LiDepartment of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
Yanan LiuDepartment of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
Deanna LarsonDepartment of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
Michiko KogaDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Takeya TsutsumiDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Eisuke AdachiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1623-873X
Makoto SaitoDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1667-9287
Shinya YamamotoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Keiko MitamuraDivision of Infection Control, Eiju General Hospital, Tokyo, Japan.
Tetsuro SatoDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Masayuki HojoDepartment of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9595-9657
Shin-Ichiro HattoriDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5637-3397
Kenji MaedaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9424-1491
Riccardo ValdezDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
IASO study team
Moe OkudaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Jurika MurakamiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Calvin DuongDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Sucheta GodboleHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Daniel C DouekHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ken MaedaDepartment of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3488-5439
Shinji WatanabeCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.
Aubree GordonDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-9352-7877
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Hiroshi YotsuyanagiDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-8791-3165
Hideki HasegawaCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0001-9274-3853
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3820-9542
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. yoshihiro.kawaoka@wisc.edu.ORCID http://orcid.org/0000-0001-5061-8296
Tokyo University of Science · JPUniversity of Michigan · USNational Institute of Infectious Diseases · JPUniversity of Wisconsin–Madison · USUtah State University · USNational Center for Global Health and Medicine · JPNational Institutes of Health · USEiju General Hospital · JPWashington University in St. Louis · US
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MTransmissibility of avian influenza viruses in mammalsR01AI069274 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KAWAOKA, YOSHIHIRO · 2006 to 2016
$5.5MDevelopment of therapeutics for SARS-CoV-2 infectionZIABC012018 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2020 to 2025
$2.6MIntramural NIH HHS ZIA BC012018NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI069274NIAID NIH HHS R01 AI157155
Abstract
The recent emergence of SARS-CoV-2 Omicron (B.1.1.529 lineage) variants possessing numerous mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies and antiviral drugs for COVID-19 against these variants
Indexed as
Antiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralCOVID-19CricetinaeCytidineDrug CombinationsHydroxylaminesIndazolesLactamsLeucineAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralAntiviral Agentscasirivimab and imdevimab drug combinationCOV2-2130COV2-2196CytidineDrug CombinationsensitrelvirHydroxylaminesIndazolesLactamsLeucinemolnupiravirnirmatrelvirNitrilesProlineSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TriazinesTriazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.